HIV PrEP With Long-Acting Injectable Cabotegravir Is Safe During Pregnancy Among Cisgender Women, Analysis Finds

MedPage Today (7/25, Kahn) reports, “HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir (CAB-LA; Apretude) appeared safe during pregnancy among cisgender women, according to an analysis of the HPTN 084 open-label extension trial.” Researchers found “composite poor pregnancy outcomes were reported in 33% of pregnancies with active CAB-LA use, 38% with prior CAB-LA use, and 27% with no previous or active CAB-LA use.” The findings were presented at the International AIDS Conference.